Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study

This publication has 7 references indexed in Scilit:

• Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events
  Journal for ImmunoTherapy of Cancer, 2025
• Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
  Clinical, Cosmetic and Investigational Dermatology, 2025
• Dupilumab for the treatment of immune checkpoint blockers' induced pruritus
  Journal of the European Academy of Dermatology and Venereology, 2023
• Management of immune-related cutaneous adverse events with dupilumab
  Journal for ImmunoTherapy of Cancer, 2023
• Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature
  Sage Open Medical Case Reports, 2023
• European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement
  Journal of the European Academy of Dermatology and Venereology, 2021
• Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database
  British Journal of Dermatology, 2019